Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $103.0 million.

  • Syndax Pharmaceuticals' Change in Acquisitions & Divestments rose 279.44% to $103.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $448.6 million, marking a year-over-year increase of 3081.77%. This contributed to the annual value of $337.3 million for FY2024, which is 2857.55% down from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Change in Acquisitions & Divestments of $103.0 million as of Q3 2025, which was up 279.44% from $133.6 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $154.9 million during Q2 2023, with a 5-year trough of $37.5 million in Q1 2021.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $89.6 million (2021), whereas its average is $90.2 million.
  • In the last 5 years, Syndax Pharmaceuticals' Change in Acquisitions & Divestments skyrocketed by 36372.69% in 2021 and then crashed by 6013.94% in 2024.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Change in Acquisitions & Divestments stood at $45.4 million in 2021, then soared by 149.45% to $113.2 million in 2022, then decreased by 0.22% to $113.0 million in 2023, then dropped by 5.01% to $107.3 million in 2024, then fell by 4.04% to $103.0 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $103.0 million for Q3 2025, versus $133.6 million for Q2 2025 and $104.7 million for Q1 2025.